{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:42:07Z","timestamp":1778938927572,"version":"3.51.4"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer is associated with a high risk of venous thromboembolism (VTE) and its recurrence. There is evidence that the prothrombotic fibrin clot phenotype, involving the formation of denser and stiffer clots relatively resistant to lysis, occurs in cancer patients, which is in part related to enhanced inflammation, oxidative stress, and coagulation activation, along with the release of neutrophil extracellular traps, indicating that fibrin-related mechanisms might contribute to cancer-associated thrombosis (CAT). Multiple myeloma and its therapy have been most widely explored in terms of altered fibrin characteristics, but prothrombotic fibrin clot features have also been reported in patients with active solid cancer, including lung cancer and gastrointestinal cancer. Patient-related factors such as advanced age, smoking, and comorbidities might also affect fibrin clot characteristics and the risk of CAT. Prothrombotic fibrin clot features have been shown to predict the detection of cancer in patients following VTE during follow-up. Cancer-specific therapies and anticoagulation can favorably modify the phenotype of a fibrin clot, which may alter the course of CAT. It is unclear whether the fibrin clot phenotype might help identify patients with CAT who are more likely to experience recurrent events. This narrative review summarizes the current knowledge on the role of fibrin clot structure and function in cancer patients in the context of CAT.<\/jats:p>","DOI":"10.1055\/s-0043-1770364","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:04:59Z","timestamp":1687565099000},"page":"402-412","source":"Crossref","is-referenced-by-count":3,"title":["Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis"],"prefix":"10.1055","volume":"50","author":[{"given":"Micha\u0142","family":"Z\u0105bczyk","sequence":"additional","affiliation":[{"name":"Thromboembolic Disorders Department, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland"},{"name":"Krakow Center for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[{"name":"Thromboembolic Disorders Department, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland"},{"name":"Krakow Center for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/nyas.13454","article-title":"Coagulation and fibrinolysis in gastric cancer","volume":"1404","author":"O Repetto","year":"2017","journal-title":"Ann N Y Acad Sci"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/biom12020259","article-title":"Venous thromboembolism and cancer: a comprehensive review from pathophysiology to novel treatment","volume":"12","author":"M E Canonico","year":"2022","journal-title":"Biomolecules"},{"issue":"15","key":"ref3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"C Ay","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Y Hisada","year":"2017","journal-title":"Blood"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0039-1688495","article-title":"Fibrin and fibrinolysis in cancer","volume":"45","author":"H C Kwaan","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2003-07-2247","article-title":"Genetics of fibrin clot structure: a twin study","volume":"103","author":"E J Dunn","year":"2004","journal-title":"Blood"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/cvr\/cvad017","article-title":"Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice","volume":"119","author":"M Z\u0105bczyk","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/biol-2020-0035","article-title":"Progress in research on the role of fibrinogen in lung cancer","volume":"15","author":"X Liu","year":"2020","journal-title":"Open Life Sci"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ctrv.2015.10.002","article-title":"Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis","volume":"41","author":"C Perisanidis","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/978-3-030-58971-4_15","article-title":"Fibrinogen and fibrin","volume":"96","author":"R I Litvinov","year":"2021","journal-title":"Subcell Biochem"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","article-title":"Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review","volume":"40","author":"J J de Vries","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/jth.14002","article-title":"An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH","volume":"16","author":"M Pieters","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/j.1538-7836.2012.04883.x","article-title":"An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values","volume":"10","author":"M Pieters","year":"2012","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"103487","DOI":"10.1016\/j.jprot.2019.103487","article-title":"Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time","volume":"208","author":"M Z\u0105bczyk","year":"2019","journal-title":"J Proteomics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"103946","DOI":"10.1016\/j.jprot.2020.103946","article-title":"Plasma fibrin clot proteomics in patients with acute pulmonary embolism: association with clot properties","volume":"229","author":"A H Bryk","year":"2020","journal-title":"J Proteomics"},{"issue":"24","key":"ref16","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"S Y Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"41","key":"ref17","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"A R Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"03","key":"ref18","first-page":"353","article-title":"[Anomaly of clot formation in a case of IgG myeloma. Influence of the isolated paraprotein on coagulation and ultrastructural study of the clot]","volume":"7","author":"C Praga","year":"1967","journal-title":"Nouv Rev Fr Hematol"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.1970.tb01587.x","article-title":"Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma","volume":"18","author":"H Lackner","year":"1970","journal-title":"Br J Haematol"},{"key":"ref20","first-page":"H1195","article-title":"Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma","volume":"266","author":"M E Carr Jr","year":"1994","journal-title":"Am J Physiol"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(96)90116-X","article-title":"Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma","volume":"128","author":"M E Carr Jr","year":"1996","journal-title":"J Lab Clin Med"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000160182","article-title":"Acquired dysfibrinogenemia secondary to multiple myeloma","volume":"120","author":"R Kotl\u00edn","year":"2008","journal-title":"Acta Haematol"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/eci.12269","article-title":"Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma","volume":"44","author":"A Undas","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MBC.0000000000000315","article-title":"Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications","volume":"26","author":"A Undas","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"D R Arachchillage","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/09537100412331272541","article-title":"Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count","volume":"15","author":"A Blann","year":"2004","journal-title":"Platelets"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00277-018-3228-6","article-title":"Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients","volume":"97","author":"D Tong","year":"2018","journal-title":"Ann Hematol"},{"issue":"02","key":"ref28","first-page":"110","article-title":"Altered plasma fibrin clot properties in essential thrombocythemia","volume":"27","author":"R Ma\u0142ecki","year":"2016","journal-title":"Platelets"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1111\/jth.12896","article-title":"Polyphosphate as modulator of hemostasis, thrombosis, and inflammation","volume":"13","author":"J H Morrissey","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1074\/jbc.M606650200","article-title":"Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin","volume":"282","author":"A A Amelot","year":"2007","journal-title":"J Biol Chem"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0049-3848(98)00005-X","article-title":"Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia","volume":"90","author":"E P\u00f3s\u00e1n","year":"1998","journal-title":"Thromb Res"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MBC.0000000000000724","article-title":"An evaluation of global coagulation assays in myeloproliferative neoplasm","volume":"29","author":"H Y Lim","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2014.04.025","article-title":"Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis","volume":"134","author":"T Rusak","year":"2014","journal-title":"Thromb Res"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/bjc.2016.143","article-title":"Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data","volume":"115","author":"A J Walker","year":"2016","journal-title":"Br J Cancer"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1160\/TH15-04-0357","article-title":"Fractal dimension (df) as a new structural biomarker of clot microstructure in different stages of lung cancer","volume":"114","author":"N A Davies","year":"2015","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref36","first-page":"16191","article-title":"The impact of the COVID-19 pandemic on surgical treatment of lung cancer","volume":"132","author":"C Piwkowski","year":"2022","journal-title":"Pol Arch Intern Med"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12032-019-1262-4","article-title":"Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking","volume":"36","author":"M Z\u0105bczyk","year":"2019","journal-title":"Med Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"8170759","DOI":"10.1155\/2019\/8170759","article-title":"Decreased levels of histidine-rich glycoprotein in advanced lung cancer: association with prothrombotic alterations","volume":"2019","author":"A Winiarska","year":"2019","journal-title":"Dis Markers"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.21037\/jtd.2018.11.19","article-title":"Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy","volume":"10","author":"G Kr\u00f3lczyk","year":"2018","journal-title":"J Thorac Dis"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s00268-019-05123-7","article-title":"Hypercoagulability After Resection Of Thoracic Malignancy: A Prospective Evaluation","volume":"43","author":"M B Mulder","year":"2019","journal-title":"World J Surg"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.thromres.2012.11.033","article-title":"Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation","volume":"131","author":"K Gronostaj","year":"2013","journal-title":"Thromb Res"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.trsl.2013.06.009","article-title":"Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation","volume":"163","author":"J Thaler","year":"2014","journal-title":"Transl Res"},{"issue":"21","key":"ref43","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1007\/s00018-014-1683-3","article-title":"Neutrophil extracellular traps in cancer progression","volume":"71","author":"J Cools-Lartigue","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"36","key":"ref44","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"T A Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref45","first-page":"14075","article-title":"Procoagulant role of neutrophil extracellular traps in patients with gastric cancer","volume":"8","author":"C Yang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/CH-211353","article-title":"Ex vivo Vitamin D supplementation improves viscoelastic profiles in prostate cancer patients","volume":"81","author":"M Hoek","year":"2022","journal-title":"Clin Hemorheol Microcirc"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3390\/cancers13071487","article-title":"Extracellular vesicle-associated tissue factor activity in prostate cancer patients with disseminated intravascular coagulation","volume":"13","author":"L Hell","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-0041-1733961","article-title":"New insights in coagulation and fibrinolysis in patients with primary brain cancer: a systematic review","volume":"48","author":"A Winther-Larsen","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref49","first-page":"2","article-title":"Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment","volume":"7","author":"H Dombret","year":"1993","journal-title":"Leukemia"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH09-06-0397","article-title":"Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics","volume":"103","author":"S Paneesha","year":"2010","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.11458","article-title":"Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry","volume":"93","author":"D Imberti","year":"2008","journal-title":"Haematologica"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/01.ATV.0000219688.43572.75","article-title":"Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects","volume":"26","author":"A Undas","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.10.014","article-title":"Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects","volume":"197","author":"J Siudut","year":"2021","journal-title":"Thromb Res"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/a-1492-6143","article-title":"Lifestyle influences changes in fibrin clot properties over a 10-year period on a population level","volume":"122","author":"A C Swanepoel","year":"2022","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.2009-0285","article-title":"Obesity and cancer","volume":"15","author":"K Y Wolin","year":"2010","journal-title":"Oncologist"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0038-1650618","article-title":"Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age","volume":"76","author":"K Fatah","year":"1996","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.thromres.2015.05.033","article-title":"The association of clot lysis time with total obesity is partly independent from the association of PAI-1 with central obesity in African adults","volume":"136","author":"P Eksteen","year":"2015","journal-title":"Thromb Res"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"18752","DOI":"10.1038\/s41598-021-98062-0","article-title":"Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort","volume":"11","author":"B Paulsen","year":"2021","journal-title":"Sci Rep"},{"issue":"06","key":"ref59","first-page":"1289","article-title":"Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis","volume":"102","author":"A Undas","year":"2009","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/ATVBAHA.109.195024","article-title":"Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation","volume":"30","author":"R S Barua","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"188778","DOI":"10.1016\/j.bbcan.2022.188778","article-title":"Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence","volume":"1877","author":"V Tavares","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pmed.0050097","article-title":"Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis","volume":"5","author":"M E Meltzer","year":"2008","journal-title":"PLoS Med"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1160\/TH17-01-0060","article-title":"Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban","volume":"117","author":"A Janion-Sadowska","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1768712","article-title":"Antithrombin deficiency is associated with prothrombotic plasma fibrin clot phenotype","author":"J Natorska","year":"2023","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref65","first-page":"16113","article-title":"Fibrin clot properties in coronary artery disease: new determinants and prognostic markers","volume":"131","author":"J B Larsen","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"796","DOI":"10.33963\/KP.a2021.0005","article-title":"Patients scheduled for TAVI tend to form abnormal fibrin clots more resistant to lysis: the impact of age","volume":"79","author":"M Jaworska-Wilczy\u0144ska","year":"2021","journal-title":"Kardiol Pol"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"A Undas","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00125-011-2301-7","article-title":"A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3","volume":"55","author":"K Hess","year":"2012","journal-title":"Diabetologia"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.33963\/KP.a2021.0088","article-title":"Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers","volume":"79","author":"P T Matusik","year":"2021","journal-title":"Kardiol Pol"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.13251","article-title":"Unprovoked venous thromboembolism and subsequent cancer risk: a population-based cohort study","volume":"14","author":"L M Sun","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.33963\/KP.a2021.0164","article-title":"How to treat incidental pulmonary embolism in cancer patients? Recent advances","volume":"79","author":"A Delluc","year":"2021","journal-title":"Kardiol Pol"},{"issue":"14","key":"ref72","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"07","key":"ref73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2017-07-798306","article-title":"Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study","volume":"131","author":"J Cieslik","year":"2018","journal-title":"Blood"},{"issue":"09","key":"ref74","first-page":"16326","article-title":"Unfavorably altered fibrin clot properties are associated with recurrent venous thromboembolism in patients following post\u2013discharge events","volume":"132","author":"K W Undas","year":"2022","journal-title":"Pol Arch Intern Med"},{"issue":"11","key":"ref75","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/jth.14579","article-title":"Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism","volume":"17","author":"S Mrozinska","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref76","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.13951","article-title":"Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients","volume":"16","author":"L M Mauracher","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref77","first-page":"16288","article-title":"How to optimize the prevention of post\u2013thrombotic syndrome: recent advances","volume":"132","author":"A FJ Iding","year":"2022","journal-title":"Pol Arch Intern Med"},{"issue":"S 01","key":"ref78","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0049-3848(20)30394-7","article-title":"Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study","volume":"191","author":"A Ilich","year":"2020","journal-title":"Thromb Res"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.04.009","article-title":"Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study","volume":"166","author":"N van Es","year":"2018","journal-title":"Thromb Res"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref81","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"G Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"07","key":"ref82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"A YY Lee","year":"2015","journal-title":"JAMA"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"106783","DOI":"10.1016\/j.vph.2020.106783","article-title":"Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism","volume":"133-134","author":"M Z\u0105bczyk","year":"2020","journal-title":"Vascul Pharmacol"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s43856-023-00242-8","article-title":"Plasma from patients with pulmonary embolism show aggregates that reduce after anticoagulation","volume":"3","author":"S R Baker","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"05","key":"ref85","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/ATVBAHA.112.245308","article-title":"Antithrombin-independent effects of heparins on fibrin clot nanostructure","volume":"32","author":"C Yeromonahos","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"ref86","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1111\/jth.15075","article-title":"Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model","volume":"18","author":"M Voigtlaender","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref87","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"J Sabatino","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"06","key":"ref89","first-page":"622","article-title":"Laboratory assessment of the direct oral anticoagulants: who can benefit?","volume":"79","author":"I J Akpan","year":"2021","journal-title":"Kardiol Pol"},{"issue":"06","key":"ref90","first-page":"377","article-title":"Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study","volume":"129","author":"P Fr\u0105czek","year":"2019","journal-title":"Pol Arch Intern Med"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2010.03739.x","article-title":"Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor","volume":"8","author":"C T Ammollo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref92","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2141.2010.08546.x","article-title":"Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate","volume":"152","author":"M Blomb\u00e4ck","year":"2011","journal-title":"Br J Haematol"},{"issue":"08","key":"ref93","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/rth2.12443","article-title":"Effect of anticoagulants on fibrin clot structure: a comparison between vitamin K antagonists and factor Xa inhibitors","volume":"4","author":"J S Gauer","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood.V112.11.3031.3031","article-title":"Improvement of thrombolysis by rivaroxaban, an anti Xa inhibitor. Potential therapeutic importance in patients with thrombosis","volume":"112","author":"R Varin","year":"2008","journal-title":"Blood"},{"issue":"11","key":"ref95","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/jth.14281","article-title":"Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity","volume":"16","author":"R LR Carter","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/CH-201030","article-title":"The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis","volume":"80","author":"V J Evans","year":"2022","journal-title":"Clin Hemorheol Microcirc"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1770364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:57:17Z","timestamp":1730807837000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1770364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":96,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,3,8]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1770364","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]}}}